BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Genova Diagnostics Announces the Acquisition of Metametrix


7/11/2012 10:27:06 AM

ASHEVILLE, N.C. and ATLANTA, July 11, 2012 /PRNewswire/ -- Genova Diagnostics, Inc. and Metametrix, Inc., leading clinical laboratories in applying a systems-based testing approach to the diagnosis, treatment and prevention of complex chronic disease, today announced they have combined efforts under one company.

"We share a mission of improving the health of patients worldwide by striving to be the best provider of comprehensive and innovative clinical laboratory services. I look forward to offering my continued support in achieving our shared goals," said J. Alexander Bralley, PhD, CEO of Metametrix. Bralley will continue working in a consulting capacity in the newly aligned organization, focusing on development of next-generation testing approaches and clinical education programs.

The combined entity will provide a broader range of testing services, as well as increase the breadth of support and resources dedicated to physicians and their patients. "Consolidating our companies significantly increases our global presence. Together, we serve over 9,000 healthcare practitioners annually throughout the United States and internationally in 45 countries with our 400 employees and three locations in Asheville, North Carolina, Duluth, Georgia, and London, England. Our combined resources will allow us to expand investments in research & development, clinical trials, medical education and market expansion," said Ted Hull, Chairman and CEO of Genova Diagnostics.

Genova Diagnostics, Inc., which purchased all assets of Metametrix, Inc., will continue to operate under both brands at this time. Financial terms of the transaction were not disclosed.

About Metametrix:

Established in 1984, Metametrix is a pioneer in producing cutting-edge technology for the measurement of nutritional insufficiencies, metabolic dysfunction, microbial imbalances and toxic influences on health. Metametrix is committed to applying the latest advances in testing services to improve health worldwide. More information about Metametrix is available at www.metametrix.com.

About Genova Diagnostics:

Established in 1986, Genova Diagnostics is a leading company in applying a systems-based approach in clinical laboratory testing for the diagnosis, treatment and prevention of complex chronic disease. Systems-based testing is offered in a number of clinical areas, including gastrointestinal, nutritional, immunologic and endocrine, addressing a range of complex chronic conditions, including pre-diabetes, cardiovascular disease, nutritional deficiencies, hormone imbalances, depression, auto-immune disease, allergies, and irritable bowel syndrome. Genova has developed a lab industry leading commercial system for building markets for innovative testing by partnering clinician education with field-based consultative selling approach.

SOURCE Metametrix, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->